0001004878-15-000203.txt : 20150630
0001004878-15-000203.hdr.sgml : 20150630
20150630131115
ACCESSION NUMBER: 0001004878-15-000203
CONFORMED SUBMISSION TYPE: 8-K
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150625
ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
FILED AS OF DATE: 20150630
DATE AS OF CHANGE: 20150630
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
FILING VALUES:
FORM TYPE: 8-K
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 15960820
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
8-K
1
form8kitem502stkop6-15.txt
8-K RE STOCK OPTIONS PER NON-QUALIFIED STK OPTION PLAN
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 25, 2015
CEL-SCI CORPORATION
------------------------------------
(Exact name of Registrant as specified in its charter)
Colorado 0-11503 84-0916344
---------------------------- --------------------- --------------------
(State or other jurisdiction (Commission File No.) (IRS Employer
of incorporation) Identification No.)
8229 Boone Boulevard, Suite 802
Vienna, Virginia 22182
------------------------------------------------
(Address of principal executive offices, including Zip Code)
Registrant's telephone number, including area code: (703) 506-9460
N/A
-----------------------------
(Former name or former address if changed since last report)
1
Item 5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On June 25, 2015, the Company, pursuant to the provisions of its
Non-Qualified Stock Option Plan, granted options to the following officers
and/or directors upon the terms shown below:
Shares Issuable
Upon Exercise Exercise Expiration
Name of Option (1) Price Date
---- --------------- -------- ---------
Maximilian de Clara 125,000 $0.66 6/21/2025
Peter Young 125,000 $0.66 6/21/2025
Alexander Esterhazy 125,000 $0.66 6/21/2025
Bruno Baillavoine 125,000 $0.66 6/21/2025
(1) Options to purchase the first 41,667 shares will be exercisable on June 22,
2016, options to purchase the next 41,667 shares will be exercisable on
June 22, 2017 and options to purchase the remaining 41,666 shares will be
exercisable on June 22, 2018. If the option holder ceases to be a director
for any reason prior to June 22, 2018, then any options which are not then
exercisable will expire.
The grant of the options was approved by the Company's Compensation
Committee and board of directors.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: June 29, 2015 CEL-SCI CORPORATION
By: /s/ Patricia B. Prichep
-------------------------------------
Patricia B. Prichep
Senior Vice President of Operations
3